低总IgE预测慢性自发性疹患者对Omalizumab的不反应:一项为期10年的实践研究
相关实验视频
Updated: May 2, 2026

07:22
Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
8.5K
International archives of allergy and immunology
|August 28, 2025
概括
奥马利祖马布有效治疗慢性自发性疹 (CSU). 较低的总IgE水平预测不反应,有助于个性化治疗CSU患者.
科学领域:
- 免疫学
- 皮肤病学
- 药理学
背景情况:
- 奥马利祖马布是抗组胺耐药慢性自发性疹 (CSU) 的关键疗法.
- 在CSU中对奥马利祖马布反应的预测生物标志物尚未确定.
- 了解治疗预测因素可以优化患者管理.
研究的目的:
- 评估奥马利祖马布在CSU患者中的实际疗效和安全性.
- 确定对奥马利祖马布治疗反应的预测因子,重点关注总IgE水平.
- 根据CSU的个性化治疗策略.
主要方法:
- 对221名接受奥马利祖马布治疗的成年CSU患者 (2015 - 2024年) 的回顾性分析.
- 通过疹活动评分 (UAS7) 和疹控制测试 (UCT) 评估临床反应.
- 与治疗结果相关的实验室参数分析,包括总IgE.
主要成果:
- 在98. 2%的患者中,Omalizumab取得了快速或晚期的反应.
- 观察到UAS7得分的显著降低和UCT得分的改善.
- 总IgE水平≤12. 5IU/ mL强烈预测没有反应 (96. 7%的特异性).
结论:
- 在实际的CSU管理中,Omalizumab表现出高效率和安全性.
- 低总IgE水平是预测奥马利祖马布不响应的可靠生物标志物.
- 生物标志物识别有助于为CSU提供个性化的治疗方法.
相关概念视频
Allergic Reactions
26.4K
Overview
26.4K
Allergic Drug Reactions
1.6K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.6K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
359
Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
359
Asthma III: Clinical Manifestations
49
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
49

